LY03020 - Luye Pharma Phase 1 Trial

LY03020 - Luye Pharma Phase 1 Clinical Trial

Overview

LY03020 - Luye Pharma Phase 1 Clinical Trial

Overview

LY03020 (also known as LPM787000048 Maleate Extended-Release) is an investigational drug being developed by Luye Pharma Group Ltd. for the treatment of Alzheimer's disease psychosis and schizophrenia. This Phase 1 clinical trial (NCT07230652) evaluates the safety, tolerability, and pharmacokinetics of multiple oral doses of LY03020 extended-release tablets in Chinese adult healthy subjects and subjects with stable schizophrenia.

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | NCT07230652 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Luye Pharma Group Ltd. |
| Intervention | LY03020 (LPM787000048 Maleate Extended-Release Tablets) |
| Enrollment | 40 participants |
| Duration | 7 days dosing + 4 days follow-up |
| Location | Beijing, China |

Study Design

This is a randomized, double-blind, placebo-controlled, dose-escalating Phase 1 clinical study with the following design characteristics:

• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Purpose: Treatment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Treatment Arms

| Arm | Description |
|-----|-------------|
| LY03020 | Experimental - Subjects will take LY03020 from Day 1 to Day 7 |
| Placebo | Comparator - Subjects will take matching placebo from Day 1 to Day 7 |

Inclusion Criteria

Healthy Subjects

• Voluntary informed consent
• Male or female aged 18 to 45 years
• Body weight ≥50.0 kg (male) / ≥45.0 kg (female)
• BMI between 18.5 and 26.0 kg/m²

Subjects with Stable Schizophrenia

• Voluntary informed consent (subject and/or guardian)
• Male or female aged 18 to 60 years
• Body weight ≥50.0 kg (male) / ≥45.0 kg (female)
• BMI between 18.5 and 32.0 kg/m²
• DSM-V criteria for primary diagnosis of schizophrenia
• PANSS total score ≤80 and CGI-S score ≤4 at screening
• Stable condition for 1 month before consent to baseline

Exclusion Criteria

Healthy Subjects

• Clinically significant medical condition or chronic disease
• Nonprescription drugs within 7 days or prescription drugs within 28 days prior to administration
• History of keratopathy, fundus disease, increased intraocular pressure, or angle-closure glaucoma
• History of orthostatic hypotension or syncope
• Clinically significant abnormal vital signs, laboratory values, or ECGs
• Positive test for HBsAg, HCV-Ab, HIV-Ab, or syphilis antibody

Subjects with Schizophrenia

• Other mental disorders except schizophrenia within 6 months (DSM-5)
• Treatment-resistant schizophrenia
• Neuroleptic malignant syndrome (NMS) history
• Anticipated need for antipsychotic regimen modifications
• Suicide attempts or suicidal ideation within past 6 months (C-SSRS questions 4 or 5)
• MAOI within 28 days or dietary supplements/TCM within 7 days
• HbA1c ≥7%
• Congenital long QT syndrome
• Uncontrolled cardiovascular disease (NYHA class II+ CHF, unstable angina, MI within 6 months)
• Resting heart rate <50 bpm
• QTc >450 ms (male) / >460 ms (female)

Outcome Measures

Primary Endpoints

• Number of participants with adverse events (AEs) and serious adverse events (SAEs)
• Time Frame: Up to Day 11

Secondary Endpoints

• Clinical laboratory assessment abnormalities
• Change in PANSS (Positive and Negative Syndrome Scale) at Day 11
• C-SSRS (Columbia-Suicide Severity Rating Scale) changes
• Barnes Akathisia Rating Scale (BARS) changes
• Simpson-Angus Scale (SAS) changes

Pharmacokinetic Endpoints

• Cmax,ss (Maximum observed concentration at steady state)
• Cmin,ss (Minimum observed concentration at steady state)
• AUC0-τ,ss (Area under concentration-time curve during dosing interval)
• AUC0-∞,ss (AUC from time zero to infinity at steady state)
• Tmax,ss (Time to maximum observed concentration)
• t1/2 (Apparent terminal elimination half-life)
• Ra(AUC) and Ra(Cmax) accumulation ratios

Safety Endpoints

• Vital sign abnormalities
• 12-lead ECG abnormalities
• Ophthalmic examination abnormalities

Mechanism of Action {#mechanism}

While the specific mechanism of action for LY03020 has not been publicly disclosed, the trial includes subjects with Alzheimer's disease psychosis and schizophrenia, suggesting the compound may target:

• Dopaminergic signaling: Given the PANSS assessment and schizophrenia indication
• Serotonergic pathways: Often implicated in psychosis treatment
• Glutamatergic modulation: NMDA receptor modulation in psychosis
• Cognitive enhancement: Relevant to Alzheimer's disease psychosis

Comparison to Similar Approaches

| Compound | Target | Indication | Phase |
|----------|--------|------------|--------|
| LY03020 | Unknown (under investigation) | AD psychosis, schizophrenia | Phase 1 |
| Pimavanserine | Inverse agonist at 5-HT2A/C | AD psychosis, schizophrenia | Phase 3 |
| Brexpiprazole | Partial agonist at 5-HT1A/D2 | Schizophrenia, AD agitation | Approved |
| Cariprazine | D3/D2 partial agonist | Schizophrenia, bipolar | Approved |
| Nuplazid | Inverse agonist at 5-HT2A |帕金森病 psychosis | Approved |

Therapeutic Rationale for AD Psychosis

Alzheimer's disease psychosis (ADP) affects up to 50% of AD patients and is characterized by:

• Visual and auditory hallucinations
• Delusions and paranoid ideations
• Behavioral disturbances
• Often indicates more rapid disease progression

• Atypical antipsychotics (off-label, limited efficacy)
• Pimavanserin (FDA approved for PDP)
• Non-pharmacological interventions
• Novel agents in development (like LY03020)

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alzheimer's Disease Psychosis](/diseases/alzheimers-disease-psychosis)
• [Schizophrenia](/diseases/schizophrenia)
• [Phase 1 Clinical Trials](/clinical-trials)
• [Pimavanserin](/therapeutics/pimavanserin)
• [Neuropsychiatric Symptoms](/symptoms/neuropsychiatric-symptoms)

References

Pharmacokinetic Considerations

The Phase 1 trial evaluates key PK parameters to establish the proper dosing regimen:

Target Profile

• Bioavailability: adequate oral absorption
• [Half-life**: suitable for once-daily or extended dosing](/genes/lif)
• Steady state: predictable accumulation ratio
• [CSF penetration**: blood-brain barrier crossing for CNS indication](/mechanisms/blood-brain-barrier)

Drug-Drug Interactions

• [CYP3A4 substrates and inhibitors](/genes/cyp3a4)
• P-glycoprotein substrates
• Food effects on absorption

Clinical Development Pathway

Phase 1 results will inform subsequent development:

Potential Phase 2

• Dose-finding in target population
• Efficacy signal detection
• Biomarker integration

Potential Phase 3

• Registration trial design
• Comparator selection
• Global enrollment strategy

Future Development Considerations

Biomarker Development for AD Psychosis

Biomarkers are critical for AD psychosis drug development:

| Biomarker Type | Utility | Status |
|----------------|---------|--------|
| CSF Aβ/tau | AD diagnosis | Validated |
| Amyloid PET | Amyloid confirmation | Approved |
| Tau PET | Tau staging | Approved |
| Neurodegeneration markers | Disease progression | Emerging |
| Neuropsychiatric biomarkers | Treatment response | Research stage |

For AD psychosis specifically, no validated biomarkers exist yet. Development would require:

• Demonstrating that the biomarker changes with treatment
• Showing correlation with clinical endpoints
• Validating in multiple populations

Combination Therapy Approaches

Given the complexity of AD psychosis, several combination strategies are under investigation:

• May address both psychosis and cognitive symptoms
• Examples: Donepezil + antipsychotic combinations

• For AD patients, targeting underlying amyloid pathology
• Lecanemab/lecanemab + antipsychotic

• Broad receptor engagement may provide better coverage
• LY03020's unknown mechanism may offer this advantage

• Cognitive behavioral therapy
• Environmental modifications
• Caregiver education

Personalized Medicine Considerations

Future development may incorporate precision medicine elements:

| Factor | Potential Application |
|--------|---------------------|
| Genetic background | CYP2D6 metabolizer status affects drug metabolism |
| Disease stage | Earlier intervention may show better results |
| Symptom profile | Specific symptom clusters may respond differently |
| Prior treatment | Response history informs selection |
| Comorbidities | Medical conditions affect safety |

Regulatory Strategy

For a dual indication (AD psychosis and schizophrenia), regulatory pathways include:

Market Access Considerations

Successful development would require:

Competitive Landscape Deep Dive

Current Treatment Paradigms

| Treatment | Indication | Limitations |
|-----------|------------|-------------|
| Atypical antipsychotics | Schizophrenia, off-label AD psychosis | Side effects, efficacy questions |
| Pimavanserin | Parkinson's disease psychosis | Limited AD data |
| Brexpiprazole | Schizophrenia, AD agitation | Not specifically for psychosis |
| Quetiapine | Off-label AD psychosis | Sedation, metabolic effects |

Emerging Therapies

| Drug | Mechanism | Development Stage | Company |
|------|-----------|-------------------|----------|
| LY03020 | Multi-target (unknown) | Phase 1 | Luye Pharma |
| Pimavanserin | 5-HT2A inverse agonist | Approved (PDP), Phase 3 (ADP) | AbbVie |
| AVP-786 | Dextromethorphan + quinidine | Phase 3 | AveXis/Novartis |
| Endoxifen | Unknown | Phase 2 | Otsuka |

Market Opportunity

The AD psychosis market represents significant unmet need:

• Prevalence: ~40-50% of AD patients develop psychosis
• Incidence: ~10% per year in moderate AD
• Impact: Associated with faster decline, earlier nursing home placement
• Current treatments: Off-label antipsychotics with limited efficacy and safety concerns
• Market size: Estimated $2-3 billion globally

Pharmacological Deep Dive

Receptor Binding Profile Considerations

Antipsychotic drugs are characterized by their receptor binding:

| Receptor | Occupancy | Clinical Effect |
|----------|-----------|-----------------|
| D2 | 60-80% | Antipsychotic effect |
| 5-HT2A | High | Reduced EPS, improved negative symptoms |
| H1 | Variable | Sedation, weight gain |
| Muscarinic | Variable | Anticholinergic effects |
| Alpha-1 | Variable | Orthostatic hypotension |

LY03020's unknown profile makes it difficult to predict effects. The inclusion of AD patients suggests awareness of cognitive effects and perhaps preferential targeting of certain receptors.

Blood-Brain Barrier Penetration

CNS drugs must cross the blood-brain barrier (BBB):

| Factor | Impact |
|--------|--------|
| Lipophilicity | Higher = better penetration |
| Molecular weight | <500 Da preferred |
| P-gp substrate | Affects efflux |
| Plasma protein binding | Higher = less free drug |

Phase 1 PK studies will determine if LY03020 achieves adequate brain exposure.

Drug Metabolism Considerations

CYPs involved in antipsychotic metabolism:

| Enzyme | Drugs Metabolized | Implications |
|--------|-------------------|--------------|
| CYP2D6 | Risperidone, aripiprazole | Genetic variability |
| CYP3A4 | Many antipsychotics | Drug interactions |
| CYP1A2 | Clozapine, olanzapine | Smoking affects levels |
| CYP2C19 | Some drugs | Genetic variability |

PK studies will identify major metabolic pathways.

Safety Profile Analysis

Antipsychotic Class Effects

All antipsychotics share certain risks:

| Risk | Mechanism | Clinical Manifestation |
|------|-----------|----------------------|
| Extrapyramidal symptoms | D2 blockade | Tremor, rigidity, akathisia |
| Hyperprolactinemia | D2 blockade | Sexual dysfunction, galactorrhea |
| Weight gain | Multiple | Obesity, metabolic syndrome |
| QTc prolongation | Cardiac ion channel block | Arrhythmia risk |
| Sedation | H1, 5-HT2A | Sleepiness, cognitive impairment |

AD-Specific Concerns

In AD patients, additional concerns arise:

Phase 1 Safety Monitoring

The trial monitors for:

| Monitoring | Frequency | Purpose |
|------------|-----------|--------|
| Vital signs | Daily | Cardiovascular safety |
| ECG | Baseline, Day 4, end | QTc monitoring |
| Labs | Day 1, Day 8 | Organ function |
| Physical exam | Screening, end | General health |
| Adverse events | Continuous | Safety assessment |

Development Timeline and Milestones

Expected Timeline

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Phase 1 | 6-12 months | Safety, PK data |
| Phase 2 | 12-18 months | Dose selection, efficacy signal |
| Phase 3 | 24-36 months | Pivotal efficacy trials |
| Registration | 12-18 months | NDA/MAA review |

Decision Points

After Phase 1, decisions include:

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alzheimer's Disease Psychosis](/diseases/alzheimers-disease-psychosis)
• [Schizophrenia](/diseases/schizophrenia)
• [Phase 1 Clinical Trials](/clinical-trials)
• [Luye Pharma](/companies/luye-pharma)
• [Pimavanserin](/therapeutics/pimavanserin)
• [Brexpiprazole](/therapeutics/brexpiprazole)
• [Atypical Antipsychotics](/therapeutics/antipsychotics)
• [Dopamine Receptors](/neurotransmitters/dopamine)
• [Serotonin Receptors](/neurotransmitters/serotonin)
• [Glutamate and NMDA](/mechanisms/glutamate-signaling)

External Links

• [ClinicalTrials.gov - NCT07230652](https://clinicaltrials.gov/study/NCT07230652)
• [Luye Pharma Group Ltd.](https://www.luye.com)
• [NMPA - China Drug Administration](https://www.nmpa.gov.cn)
• [FDA - Antipsychotic Drug Information](https://www.fda.gov/drugs)

Clinical Pharmacology Deep Dive

Pharmacodynamic Considerations

The pharmacodynamic profile of LY03020, while not fully disclosed, would be expected to include receptor binding activities typical of CNS-active antipsychotic agents. Understanding the receptor occupancy profile is crucial for predicting both therapeutic efficacy and side effect patterns.

Key Receptor Targets for Psychosis Treatment:

| Receptor | Therapeutic Effect | Side Effect Risk |
|----------|-------------------|------------------|
| D2 dopamine | Antipsychotic efficacy | EPS, hyperprolactinemia |
| 5-HT2A serotonin | Reduced EPS, improved cognition | Sedation |
| 5-HT1A partial agonism | Anxiety reduction, mood stabilization | Variable |
| H1 histamine | Sedation | Weight gain, cognitive impairment |
| Alpha-1 adrenergic | None | Orthostatic hypotension |
| Muscarinic | None | Anticholinergic effects |

The balance between D2 blockade and 5-HT2A antagonism determines the atypical antipsychotic profile. drugs with high 5-HT2A relative to D2 occupancy (like clozapine andquetiapine) typically have lower EPS risk[@serotonin_antipsychotics_2019].

Pharmacokinetic Parameters of Interest

Phase 1 Multiple Ascending Dose (MAD) studies evaluate several key PK parameters:

Cmax (Peak Concentration):

• Determines maximum plasma exposure
• Correlates with acute side effects
• Influenced by absorption rate and distribution

• Represents total drug exposure over time
• Used for dose-proportionality assessment
• Key for establishing therapeutic window

• Determines dosing frequency
• Extended-release formulations aim for 24-hour coverage
• Affects steady-state achievement time

• Important for once-daily dosing
• Ratio >1 indicates accumulation potential
• Informs steady-state dosing adjustments

Extended-Release Formulation Advantages

LY03020 uses extended-release technology, which offers several clinical benefits:

The extended-release delivery system uses matrix or reservoir technology to control drug release over time[@extended_release_technology].

Patient Population Considerations

Alzheimer's Disease Psychosis Population

AD psychosis presents unique challenges for drug development:

Clinical Characteristics:

• Visual hallucinations are common (vs. auditory in schizophrenia)
• Delusions often involve misidentification syndromes
• Behavior disturbances accompany psychotic symptoms
• Often indicates more rapid disease progression

• Increased sensitivity to antipsychotic side effects
• Cognitive impairment complicates assessment
• Comorbidities limit treatment options
• Drug-drug interactions with existing medications

• Increased mortality risk (black box warning)
• Cerebrovascular adverse events
• Cognitive worsening
• Falls and fractures

Schizophrenia Population

The schizophrenia arm provides important data:

Clinical Characteristics:

• Earlier disease onset
• Often treatment-experienced
• May have treatment-resistant subsets
• Chronic illness requiring long-term management

• Reduce positive symptoms (hallucinations, delusions)
• Address negative symptoms (avolition, flat affect)
• Improve cognitive function
• Prevent relapse

• Stable patients (PANSS ≤80) selected for safety
• Allows assessment without acute illness confounds
• Enables detection of treatment effects

Regulatory Pathway Considerations

China NMPA Requirements

As a Chinese trial, LY03020 follows NMPA guidelines:

Phase 1 Requirements:

• Safety and tolerability in healthy subjects
• Dose-finding in target population
• PK/PD characterization

• Preclinical data (pharmacology, toxicology)
• Manufacturing quality data
• Clinical protocol and investigator brochure

• Local patient population
• China-specific regulatory requirements
• Potential for conditional approval

Global Development Strategy

A dual-indication antipsychotic requires strategic planning:

Development Tracks:

| Phase | AD Psychosis | Schizophrenia |
|-------|--------------|---------------|
| Phase 1 | Combined trial | Combined trial |
| Phase 2 | Dose-finding | Dose-finding |
| Phase 3 | Pivotal trials | Pivotal trials |
| Approval | Sequential or parallel | Sequential or parallel |

Regulatory Interactions:

• Pre-IND meetings with FDA and NMPA
• Orphan drug consideration for AD psychosis
• Breakthrough therapy designation potential

Intellectual Property Considerations

Pharmaceutical development involves robust IP protection:

Patent Strategy:

• Composition of matter claims
• Formulation patents (extended-release)
• Method of treatment claims
• Crystal form patents

• Regulatory data protection periods
• Market exclusivity provisions
• Pediatric study incentives

Clinical Development Risk Assessment

Technical Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| PK failure | Low | High | Thorough PK characterization |
| Safety signals | Medium | High | Rigorous monitoring |
| Efficacy failure | Medium | High | Dose optimization |
| Formulation issues | Low | Medium | Technology validation |

Commercial Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Competition | High | Medium | Differentiated mechanism |
| Market size | Medium | High | Realistic projections |
| Pricing pressure | Medium | Medium | Value demonstration |
| Reimbursement | Medium | High | Health economics data |

Operational Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Recruitment | Medium | High | Multiple sites |
| Retention | Medium | High | Patient engagement |
| Protocol deviations | Low | Medium | Training |
| Data quality | Low | High | Monitoring |

Competitive Intelligence

Market Analysis

The antipsychotic market for AD psychosis represents significant opportunity:

Market Drivers:

• Aging population increases AD prevalence
• Limited approved treatments
• High unmet need in refractory patients
• Premium pricing potential

| Company | Drug | Indication | Status |
|---------|------|------------|--------|
| Luye Pharma | LY03020 | AD psychosis, schizophrenia | Phase 1 |
| AbbVie | Pimavanserin | ADP, PDP | Phase 3/Approved |
| Otsuka | AVP-786 | AD psychosis | Phase 3 |
| Acadia | Nuplazid | PDP | Approved |

Differentiation Opportunities:

• Novel mechanism of action
• Extended-release formulation
• Dual indication potential
• Improved safety profile

Summary and Clinical Relevance

LY03020 represents an important step in addressing the significant unmet need for safe and effective treatment of Alzheimer's disease psychosis. The Phase 1 trial design demonstrates careful attention to both safety assessment and future efficacy evaluation.

The inclusion of healthy subjects and schizophrenia patients in the same trial allows for comprehensive characterization of PK and safety across populations. The extended-release formulation offers potential advantages in tolerability and compliance.

Key success factors for subsequent development will include:

The dual-indication strategy, while ambitious, could provide significant commercial advantage if both indications prove viable. Success would address a major gap in treatment options for patients suffering from psychosis in the context of neurodegenerative disease.

See Also

Related Hypotheses:

• [Phase-Separated Organelle Targeting](/hypotheses/h-ec731b7a)
• [Stress Granule Phase Separation Modulators](/hypotheses/h-97aa8486)

• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1)
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009)
• [sda-2026-04-01-gap-006](/analysis/sda-2026-04-01-gap-006)

• [Macroautophagy Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-macroautophagy-dysfunction-parkinsons)